Inactive Instrument

Allena Pharmaceuticals, Inc.

Equities

ALNA

US0181191075

Biotechnology & Medical Research

Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference

November 15, 2021 at 04:06 pm EST

NEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will present at the Stifel 2021 Virtual Healthcare Conference being held November 15^th-17^th 2021.

Please see the details for the presentation below:

Stifel 2021 Virtual Healthcare Conference
Date:	8:40 a.m. ET
Time:	Wednesday, November 17^th, 2021
Webcast:	https://wsw.com/webcast/stifel58/alna/2067120

Management will also be available for 1x1 meetings. If you would like to request a meeting, please email stifelcorporateevents@stifel.com.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program recently initiated.

Investor Contact
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

Latest news about Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Went Out of Business	23-06-20	CI
First Amended Liquidation Plan Approved for Allena Pharmaceuticals, Inc.	23-05-18	CI
First Amended Liquidation Plan Filed by Allena Pharmaceuticals, Inc.	23-05-15	CI
Interim Combined Hearing for Disclosure Statement and Plan Approved for Allena Pharmaceuticals, Inc.	23-04-12	CI
Liquidation Plan and Disclosure Statement Filed by Allena Pharmaceuticals, Inc.	23-03-17	CI
North American Morning Briefing : Caution Continues to Dominate; Tesla Stock Extends Slide	22-12-28	DJ
North American Morning Briefing : Futures Rise -2-	22-12-21	DJ
North American Morning Briefing : Investors Wary -2-	22-12-14	DJ
North American Morning Briefing : Stocks to -2-	22-12-07	DJ
Motion for Asset Sale Approved for Allena Pharmaceuticals, Inc.	22-12-05	CI
North American Morning Briefing : Powell in Focus -2-	22-11-30	DJ
North American Morning Briefing : Stock Futures -2-	22-11-16	DJ
Bidding Procedure Approved for Allena Pharmaceuticals, Inc.	22-09-28	CI
Allena Pharmaceuticals, Inc.(NasdaqCM:ALNA) dropped from S&P TMI Index	22-09-09	CI
Allena Pharmaceuticals, Inc.(OTCPK:ALNA.Q) dropped from NASDAQ Composite Index	22-09-07	CI
Allena Pharmaceuticals, Inc. Enters into Settlement Agreement with Pontifax Medison Finance L.P. and Pontifax Medison Finance L.P	22-09-02	CI
Allena Pharmaceuticals, Inc. Terminates Employment of Richard D. Katz as Chief Financial Officer	22-09-02	CI
Allena Pharmaceuticals, Inc. Terminates Employment of Louis Brenner as Chief Executive Officer	22-09-02	CI
Allena Pharmaceuticals, Inc. Announces Management Changes	22-09-02	CI
Motion for Asset Sale Filed by Allena Pharmaceuticals, Inc.	22-09-02	CI
Allena Pharmaceuticals, Inc. Filed for Bankruptcy	22-09-02	CI
North American Morning Briefing : Retailers in -2-	22-08-16	DJ
Allena Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Allena Pharmaceuticals, Inc. Provides ALLN-346 Program Update	22-08-11	CI
Allena Pharmaceuticals Says Enrollment Complete in Two Cohorts of Gout, Chronic Kidney Disease Treatment Study	22-07-19	MT

Chart Allena Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Allena Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Company is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company's lead product candidate, ALLN-346, is an orally administered, urate-degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The Company is conducting two Phase IIa for ALLN-346. The Company's wholly owned subsidiaries include Allena Pharmaceuticals Security Corporation (Security Corporation) and Allena Pharmaceuticals Ireland Limited.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-0.19%	103B
REGENERON PHARMACEUTICALS, INC.	+3.40%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.14%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-22.95%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.98%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.95%	10.98B

Bio Therapeutic Drugs